Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Transpl Immunol ; 75: 101714, 2022 12.
Article in English | MEDLINE | ID: mdl-36108808

ABSTRACT

Acute cellular rejection (ACR) occurs in 10% of renal allograft recipients and is characterized by leukocyte infiltration as observed in needle biopsies. ACR onset is subject to several risk factors, including delayed graft function (DGF). As the impact of DGF on the etiology of ACR remains unclear, this study analyzed the association between presence of leukocyte subsets and ACR onset, in DCD kidney biopsies with extensive DGF following transplantation. Immunohistochemical analysis of protocol biopsies taken 10 days after kidney transplantation revealed that patients with high levels of renal CD163+ macrophages have a decreased risk (OR = 0.021, P = 0.008) for ACR in the first 6 months after transplantation. In pre-transplant biopsies of a comparable DCD cohort, with >80% DGF, presence of donor CD163+ macrophages showed no effect on ACR risk. Therefore, leukocyte infiltrate present during the inflammatory response at the time of DGF may contain anti-inflammatory macrophages that exert a protective effect against ACR development.


Subject(s)
Kidney Transplantation , Humans , Kidney Transplantation/adverse effects , Delayed Graft Function , Graft Survival , Graft Rejection/etiology , Tissue Donors , Kidney , Risk Factors , Macrophages , Retrospective Studies
2.
Am J Transplant ; 17(4): 1020-1030, 2017 04.
Article in English | MEDLINE | ID: mdl-27639190

ABSTRACT

In renal transplantation, use of calcineurin inhibitors (CNIs) is associated with nephrotoxicity and immunosuppression with malignancies and infections. This trial aimed to minimize CNI exposure and total immunosuppression while maintaining efficacy. We performed a randomized controlled, open-label multicenter trial with early cyclosporine A (CsA) elimination. Patients started with basiliximab, prednisolone (P), mycophenolate sodium (MPS), and CsA. At 6 months, immunosuppression was tapered to P/CsA, P/MPS, or P/everolimus (EVL). Primary outcomes were renal fibrosis and inflammation. Secondary outcomes were estimated glomerular filtration rate (eGFR) and incidence of rejection at 24 months. The P/MPS arm was prematurely halted. The trial continued with P/CsA (N = 89) and P/EVL (N = 96). Interstitial fibrosis and inflammation were significantly decreased and the eGFR was significantly higher in the P/EVL arm. Cumulative rejection rates were 13% (P/EVL) and 19% (P/CsA), (p = 0.08). A post hoc analysis of HLA and donor-specific antibodies at 1 year after transplantation revealed no differences. An individualized immunosuppressive strategy of early CNI elimination to dual therapy with everolimus was associated with decreased allograft fibrosis, preserved allograft function, and good efficacy, but also with more serious adverse events and discontinuation. This can be a valuable alternative regimen in patients suffering from CNI toxicity.


Subject(s)
Everolimus/therapeutic use , Fibrosis/drug therapy , Graft Rejection/drug therapy , Graft Survival/drug effects , Kidney Transplantation/adverse effects , Prednisolone/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Female , Fibrosis/etiology , Graft Rejection/etiology , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Prospective Studies , Time Factors , Weaning
3.
PLoS One ; 11(9): e0162166, 2016.
Article in English | MEDLINE | ID: mdl-27598902

ABSTRACT

Vascular endothelial growth factor A (VEGF-A) is essential for maintaining the glomerular filtration barrier. Absolute renal levels of VEGF-A change in patients with diabetic nephropathy and inflammatory kidney diseases, but whether changes in the renal splicing patterns of VEGF-A play a role remains unclear. In this study, we investigated mRNA splicing patterns of pro-angiogenic isoforms of VEGF-A in glomeruli and whole kidney samples from human patients with kidney disease and from mouse models of kidney disease. Kidney biopsies were obtained from patients with acute rejection following kidney transplantation, patients with diabetic nephropathy, and control subjects. In addition, kidney samples were obtained from mice with lupus nephritis, mice with diabetes mellitus, and control mice. The relative expression of each VEGF-A splice variant was measured using RT-PCR followed by quantitative fragment analysis. The pattern of renal VEGF-A splice variants was unchanged in diabetic nephropathy and lupus nephritis and was stable throughout disease progression in acute transplant rejection and diabetic nephropathy; these results suggest renal VEGF-A splicing stability during kidney disease. The splicing patterns were species-specific; in the control human kidney samples, VEGF-A 121 was the dominant isoform, whereas VEGF-A 164 was the dominant isoform measured in the mouse kidney samples.


Subject(s)
Alternative Splicing , Diabetes Mellitus, Type 2/genetics , Diabetic Nephropathies/genetics , Graft Rejection/genetics , Lupus Nephritis/genetics , Vascular Endothelial Growth Factor A/genetics , Animals , Case-Control Studies , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/pathology , Diabetes Mellitus, Type 2/surgery , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Diabetic Nephropathies/surgery , Disease Models, Animal , Disease Progression , Gene Expression , Graft Rejection/immunology , Graft Rejection/pathology , Humans , Kidney Glomerulus/metabolism , Kidney Glomerulus/pathology , Kidney Transplantation , Lupus Nephritis/metabolism , Lupus Nephritis/pathology , Mice , Species Specificity , Vascular Endothelial Growth Factor A/metabolism
4.
Ann Rheum Dis ; 75(9): 1583-94, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27338776

ABSTRACT

In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in life-threatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Disease Management , Immunosuppressive Agents/therapeutic use , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/pathology , Biopsy/standards , Humans , Plasma Exchange , Recurrence , Remission Induction/methods , Retreatment/methods
5.
QJM ; 109(5): 331-6, 2016 May.
Article in English | MEDLINE | ID: mdl-26819296

ABSTRACT

BACKGROUND: Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema. AIM: To study the safety and feasibility of bone marrow-derived autologous (BM-) MSC intravenous administration to patients with severe emphysema. DESIGN: A phase I, prospective open-label study registered at ClinicalTrials.gov as NCT01306513 Eligible patients had lung volume reduction surgery (LVRS) on two separate occasions. During the first LVRS bone marrow was collected, from which MSCs were isolated and expanded ex vivo After 8 weeks, patients received two autologous MSC infusions 1 week apart, followed by the second LVRS procedure at 3 weeks after the second BM-MSC infusion. METHODS: Up to 3 weeks after the last MSC infusion adverse events were recorded. Using immunohistochemistry and qPCR for analysis of cell and proliferation markers, emphysematous lung tissue obtained during the first surgery was compared with lung tissue obtained after the second surgical session to assess BM-MSC effects. RESULTS: From 10 included patients three were excluded: two did not receive MSCs due to insufficient MSC culture expansion, and one had no second surgery. No adverse events related to MSC infusions occurred and lung tissue showed no fibrotic responses. After LVRS and MSC infusions alveolar septa showed a 3-fold increased expression of the endothelial marker CD31 (P = 0.016). CONCLUSIONS: Autologous MSC treatment in severe emphysema is feasible and safe. The increase in CD31 expression after LVRS and MSC treatment suggests responsiveness of microvascular endothelial cells in the most severely affected parts of the lung.


Subject(s)
Mesenchymal Stem Cell Transplantation/methods , Pulmonary Emphysema/therapy , Stromal Cells/transplantation , Adult , Aged , Bone Marrow Cells/cytology , Cell Proliferation , Endothelial Cells/cytology , Endothelial Cells/metabolism , Female , Follow-Up Studies , Humans , Immunohistochemistry , Lung/blood supply , Lung/surgery , Male , Middle Aged , Neovascularization, Physiologic , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Pneumonectomy , Prospective Studies , Pulmonary Emphysema/pathology , Pulmonary Emphysema/physiopathology , Severity of Illness Index , Transplantation, Autologous , Treatment Outcome
6.
Am J Transplant ; 16(5): 1441-55, 2016 05.
Article in English | MEDLINE | ID: mdl-26607974

ABSTRACT

Acute rejection is a risk factor for inferior long-term kidney transplant survival. Although T cell immunity is considered the main effector in clinical acute rejection, the role of myeloid cells is less clear. Expression of S100 calcium-binding protein A8 (S100A8) and S100A9 was evaluated in 303 biopsies before and after transplantation from 190 patients. In two independent cohorts of patients with acute rejection (n = 98 and n = 11; mostly cellular rejections), high expression of S100 calcium-binding protein A8 (S100A8) and A9 (S100A9) was related to improved graft outcome. Mechanisms of action of the S100 molecules were investigated. In the graft and peripheral blood cells, S100A8 and S100A9 expression correlated with myeloid-derived suppressor markers. In line with this finding, recombinant S100A8 and S100A9 proteins inhibited maturation and the allogeneic T cell stimulatory capacity of dendritic cells. S100A9 enhanced the production of reactive oxygen species by macrophages, which suppressed T cell activity at low concentrations in the form of hydrogen peroxide. Intragraft S100A8 and S100A9 expression linked to reduced expression of T cell immunity and tissue injury markers and higher expression of immune regulatory molecules. This study sheds new light on the importance of myeloid cell subsets in directing the outcome of T cell-mediated acute rejection.


Subject(s)
Calgranulin A/metabolism , Calgranulin B/metabolism , Graft Rejection/etiology , Graft Survival/immunology , Kidney Transplantation/adverse effects , Myeloid-Derived Suppressor Cells/immunology , T-Lymphocytes/immunology , Adult , Biomarkers/metabolism , Calgranulin A/immunology , Calgranulin B/immunology , Case-Control Studies , Cohort Studies , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/metabolism , Graft Rejection/pathology , Humans , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/metabolism , Kidney Failure, Chronic/surgery , Kidney Function Tests , Male , Middle Aged , Prognosis , Risk Factors
7.
Am J Transplant ; 14(4): 936-42, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24712331

ABSTRACT

Early pancreas graft loss is usually attributed to technical failure while the possibility of antibody-mediated rejection (AMR) is generally overlooked. To investigate the role of AMR in early pancreas graft loss, we retrospectively assessed 256 patients with simultaneous pancreas-kidney transplantation (SPK) between 1985 and 2010 at our institute. We included 33 SPK patients who lost their pancreas graft <1 year after transplantation. AMR was diagnosed based on donor-specific antibodies, C4d and histology in 7 cases, 8 cases were suspicious for AMR and 18 pancreas graft losses were not due to AMR. Acute AMR occurred >1 month after transplantation in 6/7 cases, whereas all other causes typically led to loss <1 month after transplantation. Thrombotic lesions occurred equally among the 33 cases. In 12/18 concurrent kidney specimens, the diagnostic results paralleled those of the pancreas graft. All patients with acute AMR of the pancreas graft lost their renal grafts <1 year after transplantation. In the setting of a thrombotic event, histopathological analysis of early pancreas graft loss is advisable to rule out the possibility of AMR, particularly because a diagnosis of acute AMR has important consequences for renal graft outcomes.


Subject(s)
Graft Rejection/diagnosis , Isoantibodies/blood , Kidney Transplantation/adverse effects , Pancreas Transplantation/adverse effects , Pancreatic Diseases/complications , Postoperative Complications/diagnosis , Thrombosis/physiopathology , Adult , Allografts , Case-Control Studies , Complement C4b/immunology , Female , Follow-Up Studies , Graft Rejection/etiology , Graft Rejection/mortality , Humans , Immunity, Cellular/immunology , Isoantibodies/immunology , Male , Middle Aged , Pancreatic Diseases/surgery , Peptide Fragments/immunology , Postoperative Complications/etiology , Postoperative Complications/mortality , Prognosis , Retrospective Studies , Risk Factors , Survival Rate , Tissue Donors
9.
Am J Transplant ; 13(8): 2106-18, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23763497

ABSTRACT

Steroid-refractory acute rejection is a risk factor for inferior renal allograft outcome. We aimed to gain insight into the mechanisms underlying steroid resistance by identifying novel molecular markers of steroid-refractory acute rejection. Eighty-three kidney transplant recipients (1995-2005), who were treated with methylprednisolone during a first acute rejection episode, were included in this study. Gene expression patterns were investigated in a discovery cohort of 36 acute rejection biopsies, and verified in a validation cohort of 47 acute rejection biopsies. In the discovery set, expression of metallothioneins (MT) was significantly (p < 0.000001) associated with decreased response to steroid treatment. Multivariate analysis resulted in a predictive model containing MT-1 as an independent covariate (AUC = 0.88, p < 0.0000001). In the validation set, MT-1 expression was also significantly associated with steroid resistance (p = 0.029). Metallothionein expression was detected in macrophages and tubular epithelial cells. Parallel to the findings in patients, in vitro experiments of peripheral blood mononuclear cells from 11 donors showed that nonresponse to methylprednisolone treatment is related to highly elevated MT levels. High expression of metallothioneins in renal allografts is associated with resistance to steroid treatment. Metallothioneins regulate intracellular concentrations of zinc, through which they may diminish the zinc-requiring anti-inflammatory effect of the glucocorticoid receptor.


Subject(s)
Drug Resistance/genetics , Graft Rejection/metabolism , Kidney Failure, Chronic/therapy , Kidney Transplantation/adverse effects , Metallothionein/genetics , Methylprednisolone/adverse effects , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Biomarkers/metabolism , Case-Control Studies , Chromosomes, Human, Y , Cohort Studies , Female , Gene Expression Profiling , Graft Rejection/pathology , Humans , Immunoenzyme Techniques , In Situ Hybridization , Kidney Failure, Chronic/genetics , Male , Metallothionein/metabolism , Methylprednisolone/administration & dosage , Middle Aged , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction
10.
Am J Transplant ; 12(4): 877-87, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22225993

ABSTRACT

Ischemia/reperfusion injury (IRI) remains a major problem in renal transplantation. Clinical studies have identified that high serum levels of Mannan-binding lectin (MBL), the initiator of the lectin pathway of complement activation, are associated with inferior renal allograft survival. Using a rat model, we identified an entirely novel role for MBL in mediating renal IRI. Therapeutic inhibition of MBL was protective against kidney dysfunction, tubular damage, neutrophil and macrophage accumulation, and expression of proinflammatory cytokines and chemokines. Following reperfusion, exposure of tubular epithelial cells to circulation-derived MBL resulted in internalization of MBL followed by the rapid induction of tubular epithelial cell death. Interestingly, this MBL-mediated tubular injury was completely independent of complement activation since attenuation of complement activation was not protective against renal IRI. Our identification that MBL-mediated cell death precedes complement activation strongly suggests that exposure of epithelial cells to MBL immediately following reperfusion is the primary culprit of tubular injury. In addition, also human tubular epithelial cells in vitro were shown to be susceptible to the cytotoxic effect of human MBL. Taken together, these data reveal a crucial role for MBL in the early pathophysiology of renal IRI and identify MBL as a novel therapeutic target in kidney transplantation.


Subject(s)
Complement Activation/immunology , Mannose-Binding Lectin/adverse effects , Renal Insufficiency/etiology , Renal Insufficiency/pathology , Reperfusion Injury/etiology , Reperfusion Injury/pathology , Animals , Cell Death , Cells, Cultured , Flow Cytometry , Humans , Kidney Function Tests , Kidney Tubules/drug effects , Kidney Tubules/metabolism , Kidney Tubules/pathology , Male , Rats , Rats, Inbred Lew
11.
Am J Transplant ; 11(9): 1792-802, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21812920

ABSTRACT

The first Banff proposal for the diagnosis of pancreas rejection (Am J Transplant 2008; 8: 237) dealt primarily with the diagnosis of acute T-cell-mediated rejection (ACMR), while only tentatively addressing issues pertaining to antibody-mediated rejection (AMR). This document presents comprehensive guidelines for the diagnosis of AMR, first proposed at the 10th Banff Conference on Allograft Pathology and refined by a broad-based multidisciplinary panel. Pancreatic AMR is best identified by a combination of serological and immunohistopathological findings consisting of (i) identification of circulating donor-specific antibodies, and histopathological data including (ii) morphological evidence of microvascular tissue injury and (iii) C4d staining in interacinar capillaries. Acute AMR is diagnosed conclusively if these three elements are present, whereas a diagnosis of suspicious for AMR is rendered if only two elements are identified. The identification of only one diagnostic element is not sufficient for the diagnosis of AMR but should prompt heightened clinical vigilance. AMR and ACMR may coexist, and should be recognized and graded independently. This proposal is based on our current knowledge of the pathogenesis of pancreas rejection and currently available tools for diagnosis. A systematized clinicopathological approach to AMR is essential for the development and assessment of much needed therapeutic interventions.


Subject(s)
Autoantibodies/immunology , Graft Rejection/diagnosis , Pancreas Transplantation/immunology , Practice Guidelines as Topic , Graft Rejection/immunology , Humans
12.
Clin Exp Immunol ; 164 Suppl 1: 14-6, 2011 May.
Article in English | MEDLINE | ID: mdl-21447124

ABSTRACT

What drives human beings to classify? It seems as if it is within our nature to do so. Clinical classification systems for the systemic vasculitides were composed a long time ago, and they are constantly being revised and altered. The histopathological features of many diseases are so diverse that classification is called for. The histopathological classification for anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis was the culmination of results produced from a number of clinicopathological studies conducted within the European Vasculitis Study Group (EUVAS). The classification scheme has four general categories, named focal, crescentic, sclerotic and mixed. The first three categories are based on the predominance of normal glomeruli, glomeruli with cellular crescents and globally sclerotic glomeruli. The mixed category represents a heterogeneous phenotype of biopsies in which none of the aforementioned features is dominant. Results from a validation study incorporating 100 patients with at least 1-year follow-up showed that the phenotypical order of the four classes corresponded to the severity of renal function impairment. The new histopathological classification for ANCA-associated glomerulonephritis provides a logical structure for the categorization of patients into four subgroups defined according to glomerular features. This classification will be of use for future studies, such as clinical trials.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/classification , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/pathology , Glomerulonephritis/classification , Glomerulonephritis/pathology , Antibodies, Antineutrophil Cytoplasmic/immunology , Clinical Trials as Topic , Humans , Renal Insufficiency/classification , Renal Insufficiency/pathology , Severity of Illness Index
13.
Clin Exp Allergy ; 40(10): 1473-81, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20937062

ABSTRACT

BACKGROUND: IgE and its high-affinity receptor FcɛRI play an important role in allergy and asthma. The distribution of FcɛRI expression in the airways and within the airway wall, however, is largely unknown. OBJECTIVE: In this study, we aimed to map the distribution of FcɛRI in different layers of large airways (LA) and small airways (SA) in lung tissue from non-smoking and smoking patients who died of asthma [fatal asthma (FA)] and non-smoking controls (CTR). METHODS: Postmortem lung tissue from 24 cases of non-smoking FA, 13 smoking FA patients and from 19 subjects who died of non-pulmonary causes (CTR) was immunohistochemically stained for FcɛRI and AA1 (mast cell tryptase marker). The expression of these markers was analysed in inner, muscle, and outer layers of both LA and SA by image analysis. RESULTS: FcɛRI expression was higher in non-smoking and smoking FA compared with CTR in the inner and outer layer of SA. In the outer layer of LA, FcɛRI expression was higher in non-smoking FA compared with CTR. AA1 was higher in non-smoking FA compared with smoking FA and CTR in the outer layer of the SA, which was correlated with FcɛRI in this layer. CONCLUSION: Our results show that the expression of FcɛRI is higher in both LA and SA in FA compared with CTR. These differences are predominantly found in the outer layer where they can be attributed in part to the increased mast cell numbers. These results indicate an increased capacity to mount IgE-mediated reactions in FA, both in LA and SA.


Subject(s)
Asthma/immunology , Bronchi/immunology , Receptors, IgE/biosynthesis , Adult , Asthma/metabolism , Autopsy , Bronchi/metabolism , Female , Humans , Image Processing, Computer-Assisted , Immunohistochemistry , Male , Mast Cells/immunology , Middle Aged , Tryptases/biosynthesis
14.
Am J Transplant ; 10(7): 1660-7, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20455878

ABSTRACT

C4d+ antibody-mediated rejection following pancreas transplantation has not been well characterized. Therefore, we assessed the outcomes of 27 pancreas transplantation patients (28 biopsies), with both C4d staining and donor-specific antibodies (DSA) determined, from a cohort of 257 patients. The median follow-up was 50 (interquartile range [IQR] 8-118) months. Patients were categorized into 3 groups: group 1, patients with minimal or no C4d staining and no DSA (n = 13); group 2, patients with either DSA present but no C4d, diffuse C4d+ and no DSA or focal C4d+ and DSA (n = 6); group 3, patients with diffuse C4d+ staining and DSA (n = 9). Active septal inflammation, acinar inflammation and acinar cell injury/necrosis were significantly more abundant in group 3 than in group 2 (respective p-values: 0.009; 0.033; 0.025) and in group 1 (respective p-values: 0.034; 0.009; 0.002). The overall uncensored pancreas graft survival rate for groups 1, 2 and 3 were 53.3%, 66.7% and 34.6%, respectively (p = 0.044). In conclusion, recipients of pancreas transplants with no C4d or DSA had excellent long-term graft survival in comparison with patients with both C4d+ and DSA present. Hence, C4d should be used as an additional marker in combination with DSA in the evaluation of pancreas transplant biopsies.


Subject(s)
Complement C4b/analysis , Graft Rejection/pathology , Pancreas Transplantation/pathology , Peptide Fragments/analysis , Adult , Biopsy , Coloring Agents , Electronic Health Records , Female , Follow-Up Studies , Graft Rejection/blood , Graft Rejection/immunology , HLA Antigens/analysis , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Inflammation/etiology , Inflammation/pathology , Male , Middle Aged , Pancreas Transplantation/immunology , Postoperative Complications/immunology , Postoperative Complications/pathology , Time Factors , Transplantation, Homologous/pathology , Treatment Outcome
15.
Proc Natl Acad Sci U S A ; 107(6): 2586-91, 2010 Feb 09.
Article in English | MEDLINE | ID: mdl-20133791

ABSTRACT

Rheumatoid arthritis (RA) is a systemic autoimmune disease involving inflammation of the joints. Among the autoantibodies described in RA, anticitrullinated protein antibodies (ACPAs) are highly specific and predictive for RA. In addition, ACPAs have been implicated in the pathogenesis of RA. However, a direct functional response of immune cells from ACPA(+) RA patients toward citrullinated proteins has not been demonstrated. In this study, we show that exposure to citrullinated antigens leads to activation of basophils from ACPA(+) RA patients within 20 minutes. This was not observed after exposure of basophils to noncitrullinated control antigens or after stimulation of basophils from ACPA(-) RA patients and healthy controls. Basophil activation was correlated with the binding of citrullinated proteins to basophils. Furthermore, serum from ACPA(+) RA patients in contrast to that from ACPA(-) RA patients could specifically sensitize human FcepsilonRI expressing rat basophil cells (RBL), enabling activation by citrullinated proteins. Mast cell degranulation products such as histamine levels were enhanced in synovial fluid of ACPA(+) RA patients as compared with ACPA(-) RA and osteoarthritis patients. In addition, histamine levels in synovial fluid from ACPA(+) RA patients correlated with IgE levels, suggesting degranulation of mast cells by cross-linking IgE. Immunohistochemistry on synovial biopsies demonstrated an increased number of degranulated CD117(+) mast cells in ACPA(+) RA patients; IgE and FcepsilonRI expression in synovial mast cells from ACPA(+) RA patients was increased. In conclusion, our results show an immunological response of immune cells from ACPA(+) RA patients in a citrulline-specific manner. Moreover, these data indicate a role for IgE-ACPAs and FcepsilonRI-positive cells in the pathogenesis of RA.


Subject(s)
Arthritis, Rheumatoid/immunology , Autoantibodies/immunology , Immunoglobulin E/immunology , Peptides, Cyclic/immunology , Adult , Arthritis, Rheumatoid/blood , Autoantigens/immunology , Autoantigens/metabolism , Basophils/immunology , Basophils/metabolism , Citrulline/metabolism , Enzyme-Linked Immunosorbent Assay , Fibrinogen/immunology , Fibrinogen/metabolism , Humans , Immunoglobulin E/metabolism , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Mast Cells/immunology , Mast Cells/metabolism , Osteoarthritis/immunology , Peptides, Cyclic/metabolism , Protein Binding , Proto-Oncogene Proteins c-kit/metabolism , Receptors, IgG/metabolism , Synovial Membrane/immunology , Synovial Membrane/metabolism , Synovial Membrane/pathology
16.
Ned Tijdschr Geneeskd ; 152(36): 1973-80, 2008 Sep 06.
Article in Dutch | MEDLINE | ID: mdl-18807335

ABSTRACT

OBJECTIVE: To compare the efficacy of arthroscopic lavage plus corticosteroids (ALC), arthroscopic lavage plus placebo (ALP), and joint aspiration plus corticosteroids (JAC) in patients with arthritis of the knee, and to identify clinical or histological factors that predict outcome. DESIGN: Prospective, randomised. METHOD: Patients with arthritis of the knee (not due to gout, osteoarthritis or septic arthritis) were randomised to 1 of 3 treatment arms: ALC, ALP or JAC. The primary endpoint was time to recurrence; recurrence was defined as recurrent or persistent symptomatic knee swelling requiring local treatment, and/or non-improvement in knee joint score. Synovial tissue specimens were collected for histological analysis. RESULTS: Of the 78 patients enrolled, 3 did not receive the intended therapy and 3 were lost to follow-up. The median time to recurrence was 9.6 months in the ALC group, 3.0 months in the JAC group and 1.0 month in the ALP group. Compared with ALC, the relative risk of recurrence of arthritis (RR) was 2.2 for JAC (95% CI: 1.2-4.2; p = 0.02) and 4.7 for ALP (95% CI: 2.3-9.4; p < 0.0001). In the ALC group, extensive synovial fibrosis was associated with a higher risk of recurrence (RR 5-7; 95% CI: 1.6-20.5; p < 0.01). CONCLUSION: Arthroscopic lavage plus corticosteroids was more effective than arthroscopic lavage plus placebo or joint aspiration plus corticosteroids. The absence of synovial fibrosis predicted a beneficial response.

17.
Lupus ; 17(6): 541-7, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18539707

ABSTRACT

Chimerism occurs twice as often in the kidneys of women with lupus nephritis as in normal kidneys and may be involved in the pathogenesis of systemic lupus erythematosus. Pregnancy is considered the most important source of chimerism, but the exact relationship between pregnancy, the persistence of chimeric cells and the development of systemic lupus erythematosus has not been investigated. Renal biopsies and clinical data from patients in the First Dutch Lupus Nephritis Study were used. Chimeric cells were identified by in-situ hybridization of the Y chromosome. A questionnaire was used to obtain detailed reproductive data including pregnancy history and miscarriages. Chimerism was found in 12 of 26 (46%) renal biopsies. Of the 12 chimeric women, 5 reported a pregnancy; of 14 women who were not chimeric, 8 reported a pregnancy. Chimeric women who had been pregnant reported significantly more pregnancies than non-chimeric women who had been pregnant (P=0.04). The median age of the youngest child was higher in chimeric women (19 years) than in non-chimeric women (6 years). Despite the attention given to pregnancy histories with respect to chimerism, this study shows that in patients with systemic lupus erythematosus, a clear-cut relationship is not apparent. A considerable number of chimeric women did not report a pregnancy: in these women, other sources of chimerism must be considered. Our data support the theory that only certain subsets of chimeric cells persist into the maternal circulation after pregnancy.


Subject(s)
Chimerism , Lupus Nephritis/genetics , Adolescent , Adult , Animals , Biopsy , Chromosomes, Human, Y , Female , Humans , In Situ Hybridization , Kidney/pathology , Kidney/physiology , Lupus Nephritis/physiopathology , Middle Aged , Pregnancy
18.
Am J Transplant ; 8(6): 1237-49, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18444939

ABSTRACT

Accurate diagnosis and grading of rejection and other pathological processes are of paramount importance to guide therapeutic interventions in patients with pancreas allograft dysfunction. A multi-disciplinary panel of pathologists, surgeons and nephrologists was convened for the purpose of developing a consensus document delineating the histopathological features for diagnosis and grading of rejection in pancreas transplant biopsies. Based on the available published data and the collective experience, criteria for the diagnosis of acute cell-mediated allograft rejection (ACMR) were established. Three severity grades (I/mild, II/moderate and III/severe) were defined based on lesions known to be more or less responsive to treatment and associated with better- or worse-graft outcomes, respectively. The features of chronic rejection/graft sclerosis were reassessed, and three histological stages were established. Tentative criteria for the diagnosis of antibody-mediated rejection were also characterized, in anticipation of future studies that ought to provide more information on this process. Criteria for needle core biopsy adequacy and guidelines for pathology reporting were also defined. The availability of a simple, reproducible, clinically relevant and internationally accepted schema for grading rejection should improve the level of diagnostic accuracy and facilitate communication between all parties involved in the care of pancreas transplant recipients.


Subject(s)
Graft Rejection/classification , Graft Rejection/pathology , Pancreas Transplantation , Pancreas/pathology , Transplantation, Homologous/pathology , Biopsy , Graft Rejection/diagnosis , Humans
19.
Kidney Int ; 73(12): 1426-33, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18354379

ABSTRACT

Treatment of patients with IgA nephropathy (IgAN) depends on a reliable assessment of disease progression based on measurements of glomerular filtration rate (GFR), proteinuria, hypertension, and tubulointerstitial changes. We sought to determine whether progression could be predicted from analysis of glomerular and tubulointerstitial inflammation in biopsies taken at an early stage of IgAN. We retrospectively analyzed biopsies from 50 patients, relating the subsequent clinical course to infiltration with B- and T-lymphocytes, granule membrane protein of 17 kDa (GMP-17) positive cytotoxic T cells, macrophages, fibroblasts, and tubulointerstitial expression of human leukocyte antigen-D related (HLA-DR). At biopsy, 19 patients had decreased GFR while 13 of 31 patients with normal GFR and progressive IgAN differed significantly from 18 non-progressors in the level of proteinuria and in the severity of scores for mesangial proliferation, tubular atrophy, interstitial fibrosis, and interstitial infiltrates. On multivariate regression analysis these differences disappeared; however, associations with GMP-17-positive cytotoxic T-lymphocytes in intact renal tubules and of B-lymphocytes in the interstitium remained significant. Our study may have identified a marker of disease progression in early stages of IgAN.


Subject(s)
Glomerulonephritis, IGA/pathology , Kidney Tubules/pathology , Membrane Proteins/analysis , T-Lymphocytes, Cytotoxic/immunology , Biomarkers/analysis , Disease Progression , Female , Glomerular Filtration Rate , Glomerulonephritis, IGA/immunology , Glomerulonephritis, IGA/physiopathology , HLA-DR Antigens/analysis , Humans , Kidney Tubules/immunology , Kidney Tubules/physiopathology , Male , Prognosis , Regression Analysis , Retrospective Studies
20.
Arthritis Rheum ; 58(1): 53-60, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18163491

ABSTRACT

OBJECTIVE: To compare synovial tissue infiltrates from patients with anti-cyclic citrullinated peptide (anti-CCP)-positive rheumatoid arthritis (RA) with those from patients with anti-CCP-negative RA. METHODS: Synovial tissue samples were obtained arthroscopically from the inflamed knee joints of 57 patients with RA (34 of whom were anti-CCP positive) and examined for several histologic features along with immunohistologic expression of cell markers. Joint damage was assessed using the Kellgren/Lawrence (K/L) scale (range 0-4) on standard anteroposterior radiographs. In 31 patients (18 of whom were anti-CCP positive), synovial tissue was available from an earlier time point, allowing analysis of temporal changes. RESULTS: Synovial tissue from anti-CCP-positive patients was characterized by a higher mean number of infiltrating lymphocytes (61.6 versus 31.4/high-power field [hpf] [400x]; P=0.01), less extensive fibrosis (mean score of 1.2 versus 2.0; P=0.04), and a thinner synovial lining layer (mean score of 2.1 versus 3.3; P=0.002) compared with synovial tissue from anti-CCP-negative patients. Anti-CCP-positive patients expressed more CD3, CD8, CD45RO, and CXCL12. More anti-CCP-positive patients had a K/L score >1 compared with anti-CCP-negative patients. The difference in the mean lymphocyte counts was already present a mean of 3.8 years before the index biopsy (76.7 lymphocytes/hpf and 26.7 lymphocytes/hpf in anti-CCP-positive patients and anti-CCP-negative patients, respectively; P=0.008) and was independent of disease duration and K/L score. CONCLUSION: Synovitis in patients with anti-CCP-positive RA differs from that in patients with anti-CCP- negative RA, notably with respect to infiltrating lymphocytes, and is associated with a higher rate of local joint destruction.


Subject(s)
Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , Peptides, Cyclic/metabolism , Synovitis/metabolism , Synovitis/pathology , Adult , Aged , Arthritis, Rheumatoid/immunology , Female , Fibrosis , Humans , Immunohistochemistry , Lymphocytes/pathology , Male , Middle Aged , Osteoarthritis/immunology , Osteoarthritis/metabolism , Osteoarthritis/pathology , Peptides, Cyclic/immunology , Synovial Membrane/immunology , Synovial Membrane/metabolism , Synovial Membrane/pathology , Synovitis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...